Don't get too excited Ryzen, you might need a pill ;p
I was speaking generally, if it helps you or anyone else I could have worded it as 'The recent November $20M placement will support initiation of their European Phase IIb/III trial, however, Antisense may require additional funds to support study completion. ' Such as further raising of some sort to be determined, or through options...
I hope that helps.
By the way, I wasn't arguing a point, I was answering the question you addressed to me.
CR Shortfall, page-66
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.004(5.88%) |
Mkt cap ! $62.20M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.2¢ | 6.9¢ | $91.71K | 1.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 18695 | 1 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
0.004 ( 3.20 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.2¢ | 6.9¢ | 129842 | ||
| Last updated 15.32pm 29/04/2024 ? | |||||
| PER (ASX) Chart |